NYSE:NVOPharmaceuticals
Novo Nordisk Faces Legal And FDA Challenges As Valuation Gap Widens
Novo Nordisk (NYSE:NVO) has filed a broad lawsuit against Hims & Hers, seeking to stop sales of compounded and unapproved alternatives to its obesity drug Wegovy.
The lawsuit follows recent FDA action that led Hims & Hers to discontinue its compounded GLP-1 offerings.
Separately, the FDA has issued a formal warning to Novo Nordisk over allegedly misleading advertising related to the Wegovy pill.
These developments raise questions around patient safety, the legality of compounded GLP-1...